Join our daily newsletter At The Bell to receive exclusive market insights
- PharmAust’s (PAA) upcoming human trials receives a major boost as the company’s GMP monepantel (MPL) tablets has been produced at a smaller size
- A total of 2000 smaller tablets were successfully produced using the same process as the larger tablets
- The smaller tablets are for the upcoming trials of motor neuron disease (MND) and COVID-19 clinical trials are underway
- The GMP tablet manufacturing is on schedule for February 2022
- PharmAust is down 1.02 per cent and trading at 9.7 cents per share
PharmAust’s (PAA) upcoming human trials have received a major boost as the company’s GMP monepantel (MPL) tablets has been produced at a smaller size.
A total of 2000 smaller tablets were successfully produced using the same process as the larger tablets.
The smaller tablets are for the upcoming trials of motor neuron disease (MND) and COVID-19 clinical trials are underway.
PharmAust said the GMP tablet manufacturing is on schedule for February 2022.
Chief Scientific Officer Richard Mollard said this is a great outcome for the company to convert the large tablets to smaller ones so quickly.
“The smaller dose tablets were also shape-modified to facilitate swallowing for individuals with motor neuron disease,” Dr Mollard said.
“Having the stability set up for the demonstration batch now means that PharmAust is looking forward to having three month accelerated stability studies completed in time to support an early start to the clinical trials once the GMP tablet batch is finalised.”
Last month, PharmAust set a start date for the upcoming clinical trials.
The MND trial start date is anticipated in early May 2022 and the COVID-19 trial expected to begin in May 2022.
On the market this morning, PharmAust was down 1.02 per cent and is trading at 9.7 cents per share at 2:40 pm AEDT.
